Gatekeeper function of the RUNX1 transcription factor in acute leukemia

被引:29
作者
Niebuhr, Birte [1 ]
Fischer, Meike [1 ]
Taeger, Maike [1 ]
Carnmenga, Jorg [2 ]
Stocking, Carol [1 ]
机构
[1] Heinrich Pette Inst, D-25051 Hamburg, Germany
[2] Lund Univ, Lund Strateg Ctr Stem Cell Biol & Cell Therapy, SE-221 Lund, Sweden
关键词
leukemia stem cell; core-binding factor; differentiation; self-renewal;
D O I
10.1016/j.bcmd.2007.07.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The RUNX1 gene encodes the alpha subunit of the core binding factor (CBF) and is a common target of genetic mutations in acute leukemia. We propose that RUNX1 is a gatekeeper gene, the disruption of which leads to the exodus of a subset of hematopoietic progenitors with increased self-renewal potential from the normal environmental controls of homeostasis. This pool of "escaped" cells is the target of secondary mutations, accumulating over time to induce the aggressive manifestation of acute leukemia. Evidence from patient and animal studies supports the concept that RUNX1 Mutations are the initiating event in different leukemia subtypes, but also suggests that diverse mechanisms are used to subvert RUNX1 function. One common result is the inhibition of differentiation-but its effect impinges on different lineages and stages of differentiation, depending on the mutation or fusion partner. A number of different approaches have led to the identification of secondary events that lead to the overt acute phase; however, the majority is unknown. Finally, the concept of the "leukemia stern cell" and its therapeutic importance is discussed in light of the RUNX1 gatekeeper function. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 81 条
[51]   Point mutations in the RUNX1/AML1 gene:: another actor in RUNX leukemia [J].
Osato, M .
ONCOGENE, 2004, 23 (24) :4284-4296
[52]   The 8; 21 translocation in leukemogenesis [J].
Peterson, LF ;
Zhang, DE .
ONCOGENE, 2004, 23 (24) :4255-4262
[53]   AML1 deletion in adult mice causes splenomegaly and lymphomas [J].
Putz, G ;
Rosner, A ;
Nuesslein, I ;
Schmitz, N ;
Buchholz, F .
ONCOGENE, 2006, 25 (06) :929-939
[54]   The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia [J].
Raynaud, S ;
Cave, H ;
Baens, M ;
Bastard, C ;
Cacheux, V ;
Grosgeorge, J ;
GuidalGiroux, C ;
Guo, CY ;
Vilmer, E ;
Marynen, P ;
Grandchamp, B .
BLOOD, 1996, 87 (07) :2891-2899
[55]   Effect of transcription-factor concentrations on leukemic stem cells [J].
Rosenbauer, F ;
Koschmieder, S ;
Steidl, U ;
Tenen, DG .
BLOOD, 2005, 106 (05) :1519-1524
[56]   M0 AML, clinical and biologic features of the disease, including AML1 gene mutations:: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH) [J].
Roumier, C ;
Eclache, V ;
Imbert, M ;
Davi, F ;
MacIntyre, E ;
Garand, R ;
Talmant, P ;
Lepelley, P ;
Lai, JL ;
Casasnovas, O ;
Maynadie, M ;
Mugneret, F ;
Bilhou-Naberra, C ;
Valensi, F ;
Radford, I ;
Mozziconacci, MJ ;
Arnoulet, C ;
Duchayne, E ;
Dastugue, N ;
Cornillet, P ;
Daliphard, S ;
Garnache, F ;
Boudjerra, N ;
Jouault, H ;
Fenneteau, O ;
Pedron, B ;
Berger, R ;
Flandrin, G ;
Fenaux, P ;
Preudhomme, C .
BLOOD, 2003, 101 (04) :1277-1283
[57]   New mechanisms of AML1 gene alteration in hematological malignancies [J].
Roumier, C ;
Fenaux, P ;
Lafage, M ;
Imbert, M ;
Eclache, V ;
Preudhomme, C .
LEUKEMIA, 2003, 17 (01) :9-16
[58]   The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice [J].
Schessl, C ;
Rawat, VPS ;
Cusan, M ;
Deshpande, A ;
Kohl, TM ;
Rosten, PM ;
Spiekermann, K ;
Humphries, RK ;
Schnittger, S ;
Kern, W ;
Hiddemann, W ;
Quintanilla-Martinez, L ;
Bohlander, SK ;
Feuring-Buske, M ;
Buske, C .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (08) :2159-2168
[59]   AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency [J].
Schwieger, M ;
Löhler, J ;
Friel, J ;
Scheller, M ;
Horak, I ;
Stocking, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (09) :1227-1240
[60]   Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11 [J].
Shigesada, K ;
van de Sluis, B ;
Liu, PP .
ONCOGENE, 2004, 23 (24) :4297-4307